DK0414607T3 - Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf - Google Patents

Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf

Info

Publication number
DK0414607T3
DK0414607T3 DK90402329.8T DK90402329T DK0414607T3 DK 0414607 T3 DK0414607 T3 DK 0414607T3 DK 90402329 T DK90402329 T DK 90402329T DK 0414607 T3 DK0414607 T3 DK 0414607T3
Authority
DK
Denmark
Prior art keywords
sense oligonucleotide
tnf
medicament
manufacture
well
Prior art date
Application number
DK90402329.8T
Other languages
Danish (da)
English (en)
Inventor
Pierre Smets
Abdel Karim Braham
Rene Zalisz
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of DK0414607T3 publication Critical patent/DK0414607T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • HELECTRICITY
    • H02GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02KDYNAMO-ELECTRIC MACHINES
    • H02K2203/00Specific aspects not provided for in the other groups of this subclass relating to the windings
    • H02K2203/03Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Thin Magnetic Films (AREA)
DK90402329.8T 1989-08-23 1990-08-22 Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf DK0414607T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911171A FR2651130B1 (fr) 1989-08-23 1989-08-23 Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Publications (1)

Publication Number Publication Date
DK0414607T3 true DK0414607T3 (da) 1995-06-06

Family

ID=9384878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90402329.8T DK0414607T3 (da) 1989-08-23 1990-08-22 Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf

Country Status (19)

Country Link
US (1) US5705389A (de)
EP (1) EP0414607B1 (de)
JP (1) JPH0391485A (de)
KR (1) KR0151153B1 (de)
CN (1) CN1028760C (de)
AT (1) ATE120201T1 (de)
AU (1) AU642423B2 (de)
CA (1) CA2023899C (de)
DE (1) DE69017983T2 (de)
DK (1) DK0414607T3 (de)
ES (1) ES2069715T3 (de)
FR (1) FR2651130B1 (de)
GR (1) GR3015527T3 (de)
HU (1) HU215242B (de)
IE (1) IE68592B1 (de)
IL (1) IL95342A (de)
PT (1) PT95067B (de)
RU (1) RU2066325C1 (de)
ZA (1) ZA906675B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250722B (it) * 1991-07-30 1995-04-21 Univ Degli Studi Milano Oligonucleotidi antisenso
TW323284B (de) * 1992-03-23 1997-12-21 Novartis Ag
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU1249299A (en) * 1997-11-25 1999-06-15 Brax Genomics Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
CN101235064B (zh) * 2008-02-27 2011-08-10 东南大学 可脱保护的硫代核苷酸单体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090789A1 (de) * 1982-03-26 1983-10-05 Monsanto Company Chemische DNA-Synthese
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
FR2584090B1 (fr) 1985-06-27 1987-08-28 Roussel Uclaf Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
EP0424473B1 (de) * 1988-07-05 1996-05-08 Baylor College Of Medicine Verfahren zur identifizierung von bakterien

Also Published As

Publication number Publication date
CN1049668A (zh) 1991-03-06
FR2651130B1 (fr) 1991-12-13
HU905302D0 (en) 1991-02-28
AU6119090A (en) 1991-02-28
ES2069715T3 (es) 1995-05-16
PT95067A (pt) 1991-04-18
JPH0391485A (ja) 1991-04-17
HU215242B (hu) 1998-11-30
CA2023899C (fr) 2002-05-14
RU2066325C1 (ru) 1996-09-10
ZA906675B (en) 1991-10-30
IL95342A (en) 1995-01-24
FR2651130A1 (fr) 1991-03-01
PT95067B (pt) 1997-05-28
KR0151153B1 (ko) 1998-08-17
EP0414607A3 (en) 1991-04-03
HUT56113A (en) 1991-07-29
ATE120201T1 (de) 1995-04-15
CA2023899A1 (fr) 1991-02-24
EP0414607A2 (de) 1991-02-27
AU642423B2 (en) 1993-10-21
IL95342A0 (en) 1991-06-30
DE69017983T2 (de) 1995-09-28
EP0414607B1 (de) 1995-03-22
IE68592B1 (en) 1996-06-26
DE69017983D1 (de) 1995-04-27
KR910004198A (ko) 1991-03-28
US5705389A (en) 1998-01-06
CN1028760C (zh) 1995-06-07
GR3015527T3 (en) 1995-06-30
IE903036A1 (en) 1991-02-27

Similar Documents

Publication Publication Date Title
DK0414607T3 (da) Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
KR960700062A (ko) 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
MY107056A (en) Lactam free cyclic amino acids.
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
HUT52040A (en) Process for producing diaryl-derivatives and pharmaceutical compositions containing them
FR2656609B1 (fr) Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
PT92303A (pt) Processo para a preparacao de derivados de xantina
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
DK165744C (da) Thienopyrimidinderivater, fremgangsmaader til fremstilling deraf og farmaceutiske praeparater
ZA889521B (en) Polystyrene polymers and their use as cholesterol lowering agents
EP0328913A3 (de) Neue basisch substituierte 5-Halogen-Thienoisothiazol-3(2H)-on-1,1-dioxide, ein Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB8608893D0 (en) D-nor-7-ergoline derivatives
EP0202950A3 (en) Berban derivatives and their preparation and pharmaceutical formulation
IT1222414B (it) Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
HUP0004796A2 (hu) Antipszichotikus hatású helyettesített piperidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
EP0204172A3 (en) Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use
BR9812321A (pt) Modulação de respostas imunológicas
TH4444A (th) อนุพันธ์ใหม่ของเบนซิมิดาโซลที่ทำให้เสถียรขึ้น
KR890005123A (ko) 세펨 화합물 및 이의 제조방법
ES8900140A1 (es) Un procedimiento para preparar compuestos de azatricicloalqueno.